CVE-2025-61940
NMIS/BioDose V22.02 and previous versions rely on a common SQL Server user account to access data in the database. User access in the client application is restricted by a password authentication check in the client software but the underlying database connection always has access. The latest version of NMIS/BioDose introduces an option to use Windows user authentication with the database, which would restrict this database connection.
Scoring
- Severity
- HIGH
- CVSS base score
- 8.7
- CVSS vector
- CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N
- EPSS probability
- 0.32%
- CWE
- CWE-603
- Published
- 2025-12-02
- Last modified
- 2026-03-12
Affected products
- Mirion Medical EC2 Software NMIS BioDose
- Mirion Medical EC2 Software NMIS BioDose
Weakness type
Related vulnerabilities
- CVE-2026-66305 — Skype for Business Spoofing Vulnerability
- CVE-2026-76945 — Ebyte NE2-D11 Use of Client-Side Authentication
- CVE-2026-71187 — Ebyte NA111-M Use of Client-Side Authentication
- CVE-2026-42098 — Authorization Bypass in Sparx Enterprise Architect
- CVE-2026-8830 — Keycloak: org.keycloak/keycloak-services: keycloak: policy bypass during webauthn credential registration via client-side javascript manipulation
- CVE-2026-40551 — Use of Client-Side Authentication in mpGabinet
- CVE-2025-30042 — Session generation possible with certificate number only
- CVE-2026-1363 — JNC｜IAQS and I6 - Client-Side Enforcement of Server-Side Security